Mercury set for £235m launch, TLB set at 600bp
The next deal to launch in the European leveraged loan market — Cinven’s buy-out of Mercury Pharma — will offer a margin of 600bp on its term loan ‘B’, providing relief to institutional lenders worried that the double reverse flex on Bartec’s bullet tranche could start a drastic downward pricing trend.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
